ReviewAutophagy reports2026
Autophagy in the liver.
Review in Autophagy reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The liver plays a dynamic role in maintaining whole-body homeostasis through its control of nutrient metabolism, detoxification, and immune regulation. Autophagy, a conserved lysosomal degradation pathway, is central to these functions, enabling hepatocytes to adapt to fluctuations in nutrient availability, hormonal signals, and cellular stress. Hepatic autophagy is tightly regulated by nutrient and energy-sensing pathways, including AMPK, mTOR, the coordinated actions of insulin and glucagon, and transcriptional regulators TFEB, FOXO proteins, PPAR isoforms, FXR, and NRF2. Epigenomic mechanisms, chromatin remodeling complexes, and post-transcriptional regulators, such as microRNAs (miRNAs), RNA-binding proteins (RBPs), and liquid-liquid phase separation (LLPS), further refine autophagy gene expression and autophagosome formation. In physiological conditions, autophagy maintains hepatocyte integrity by supporting lipid, carbohydrate, and protein turnover and by clearing damaged or excess organelles through selective pathways such as mitophagy, lipophagy, pexophagy, ER-phagy, and xenophagy. Autophagy dysfunction contributes to the development of various liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), cholestatic liver disease, liver fibrosis, and hepatocellular carcinoma (HCC). Understanding the diverse regulatory networks governing hepatic autophagy, along with the roles of autophagy in liver homeostasis, provides new opportunities for therapeutic intervention. This review summarizes existing findings on the role of autophagy in the liver, focusing on recent advances in the regulation of hepatic autophagy. It also highlights unresolved mechanisms and discusses how targeting autophagy may offer novel strategies for treating liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.